296
Participants
Start Date
October 31, 2006
Primary Completion Date
February 28, 2010
Study Completion Date
January 31, 2011
Risperidone
Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
Placebo
Placebo
VA Maryland Health Care System, Baltimore, Baltimore
VA Medical Center, Durham, Durham
Atlanta VA Medical and Rehab Center, Decatur, Decatur
VA Medical Center, Miami, Miami
VA Medical Center, Tuscaloosa, Tuscaloosa
Wlliam S. Middleton Memorial Veterans Hospital, Madison, Madison
VA Medical Center, Minneapolis, Minneapolis
Jesse Brown VAMC (WestSide Division), Chicago
Central Texas Veterans Health Care System, Temple
Michael E. DeBakey VA Medical Center (152), Houston
VA South Texas Health Care System, San Antonio, San Antonio
VA Salt Lake City Health Care System, Salt Lake City, Salt Lake City
VA Greater Los Angeles Healthcare System, West LA, West Los Angeles
VA San Diego Healthcare System, San Diego, San Diego
VA Medical Center, San Francisco, San Francisco
VA Connecticut Health Care System (West Haven), West Haven
VA Medical Center, Jamaica Plain Campus, Boston
New Mexico VA Health Care System, Albuquerque, Albuquerque
VA Medical Center, Providence, Providence
Ralph H Johnson VA Medical Center, Charleston, Charleston
Janssen, LP
INDUSTRY
US Department of Veterans Affairs
FED